2,990 research outputs found

    Profil Kesehatan Sapi Indukan Belgian Blue di Indonesia terhadap Penyakit Hewan Menular

    Get PDF
    Peningkatan efisiensi reproduksi dan genetik ternak melalui pengembangan sapi Belgian Blue (BB) melalui transfer embrio (TE) dan inseminasi buatan (IB) telah dilakukan di Indonesia sejak tahun 2017. Untuk menghasilkan anak sapi BB yang sehat diperlukan indukan sapi yang sehat dan bebas terhadap penyakit hewan menular. Tujuan penelitian ini adalah melakukan pengujian penyakit menular brucellosis, leptospirosis, campylobacteriosis, paratuberculosis, septicemic epizootica (SE), bovine viral diare (BVD), infectious bovine rhinothraceitis (IBR), enzootic bovine leucosis (EBL), trichomoniasis, anaplasmosis, babesiosis, theleriasis, surra dan parasit cacing (strongyle, parampistomum, cestoda, fasciola) sapi calon indukan BB di pusat pengembangan sapi BB di Indonesia. Sebanyak 291 indukan sapi dikoleksi sampel serum, darah, swab vagina dan feses diuji di laboratorium BBLitvet. Hasil pengujian terhadap 291 sampel yang dikoleksi menunjukkan tidak terdeteksi brucellosis, EBL, trichomoniasis dan surra, namun terdeteksi antibodi terhadap IBR 40,89% (119/291), BVD 70,79% (206/291), SE 56,36% (164/291), leptospirosis 41,24% (120/291) dan paratuberculosis 0,69% (2/291). Pengujian terhadap parasit darah terdeteksi anaplasmosis 41,92% (122/291), babesiosis 28,18% (82/291) dan theleriasis 30,24% (88/291)

    Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.

    Get PDF
    BACKGROUND: The effectiveness of SARS-CoV-2 vaccines in older adults living in long-term care facilities is uncertain. We investigated the protective effect of the first dose of the Oxford-AstraZeneca non-replicating viral-vectored vaccine (ChAdOx1 nCoV-19; AZD1222) and the Pfizer-BioNTech mRNA-based vaccine (BNT162b2) in residents of long-term care facilities in terms of PCR-confirmed SARS-CoV-2 infection over time since vaccination. METHODS: The VIVALDI study is a prospective cohort study that commenced recruitment on June 11, 2020, to investigate SARS-CoV-2 transmission, infection outcomes, and immunity in residents and staff in long-term care facilities in England that provide residential or nursing care for adults aged 65 years and older. In this cohort study, we included long-term care facility residents undergoing routine asymptomatic SARS-CoV-2 testing between Dec 8, 2020 (the date the vaccine was first deployed in a long-term care facility), and March 15, 2021, using national testing data linked within the COVID-19 Datastore. Using Cox proportional hazards regression, we estimated the relative hazard of PCR-positive infection at 0-6 days, 7-13 days, 14-20 days, 21-27 days, 28-34 days, 35-48 days, and 49 days and beyond after vaccination, comparing unvaccinated and vaccinated person-time from the same cohort of residents, adjusting for age, sex, previous infection, local SARS-CoV-2 incidence, long-term care facility bed capacity, and clustering by long-term care facility. We also compared mean PCR cycle threshold (Ct) values for positive swabs obtained before and after vaccination. The study is registered with ISRCTN, number 14447421. FINDINGS: 10 412 care home residents aged 65 years and older from 310 LTCFs were included in this analysis. The median participant age was 86 years (IQR 80-91), 7247 (69·6%) of 10 412 residents were female, and 1155 residents (11·1%) had evidence of previous SARS-CoV-2 infection. 9160 (88·0%) residents received at least one vaccine dose, of whom 6138 (67·0%) received ChAdOx1 and 3022 (33·0%) received BNT162b2. Between Dec 8, 2020, and March 15, 2021, there were 36 352 PCR results in 670 628 person-days, and 1335 PCR-positive infections (713 in unvaccinated residents and 612 in vaccinated residents) were included. Adjusted hazard ratios (HRs) for PCR-positive infection relative to unvaccinated residents declined from 28 days after the first vaccine dose to 0·44 (95% CI 0·24-0·81) at 28-34 days and 0·38 (0·19-0·77) at 35-48 days. Similar effect sizes were seen for ChAdOx1 (adjusted HR 0·32, 95% CI 0·15-0·66) and BNT162b2 (0·35, 0·17-0·71) vaccines at 35-48 days. Mean PCR Ct values were higher for infections that occurred at least 28 days after vaccination than for those occurring before vaccination (31·3 [SD 8·7] in 107 PCR-positive tests vs 26·6 [6·6] in 552 PCR-positive tests; p<0·0001). INTERPRETATION: Single-dose vaccination with BNT162b2 and ChAdOx1 vaccines provides substantial protection against infection in older adults from 4-7 weeks after vaccination and might reduce SARS-CoV-2 transmission. However, the risk of infection is not eliminated, highlighting the ongoing need for non-pharmaceutical interventions to prevent transmission in long-term care facilities. FUNDING: UK Government Department of Health and Social Care
    • 

    corecore